Articles On Optiscan Imaging (ASX:OIL)

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to CEO + Managing Director at Optiscan (ASX:OIL) Dr Camile Farah, who is also a trained clinic...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

S&P/ASX 200 rose 1% in June with large caps leading gains with mid, small and emerging companies lagging S&P/ASX 200 financials and consumer staples were the top performers in June with materials the biggest laggard Urea fertiliser...

The ASX200 closed the day in the red, down 0.3%. It was a rough day for the Energy sector, falling 1.6%, with Materials down 0.9%. The Financial and Staples sectors were the only ones that pushed into the green, both up around 0.2%. I...

Aussie shares down on weaker commodities Iron ore and energy stocks slip, while goldies gain Intel CEO Pat Gelsingers takes swipe at Nvidia’s CEO Jensen Huang   Aussie shares dropped slightly on Tuesday, closing -0.2% lower as the impact...

Optiscan (ASX: OIL) has unveiled InVue,  a new microscopic medical imaging device, designed to enable precision surgery by putting real-time digital pathology access directly into the hands of surgeons. Designed and manufactured in Melbo...

Optiscan unveils the InVue next-gen microscopic medical imaging device for precision surgery InVue broadens Optiscan’s product portfolio into the surgical application market, a significant step forward in achieving its strategic objectives...

Optiscan Imaging (ASX: OIL) has revealed the InVue microscopic medical imaging device, designed to benefit the surgical market by providing real-time digital pathology access to surgeons. The Australian-made device was developed in partners...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Optiscan enters know-how agreement with world-renowned Mayo Clinic for major pathology breakthrough Two organisations working to develop a digital confocal laser endomicroscopic imaging system for robotic surgery Optiscan has become a lead...

The ASX200 closed fractionally up by 0.01 of a per cent. Energy had a rough run – slipping around a per cent – while consumer discretionary and healthcare climbed around half a per cent. In the green West Australian gold producer R...

ASX flat on Monday,  ahead of Federal Budget Tuesday night Oil weakness drags Energy sector lower Chinese shares slump on new US tariffs   After advancing 1.5% last week, the ASX200 fell flat on Monday – greenish by 0.01% – dragged down m...

Optiscan Imaging (ASX:OIL) is set to partner with Mayo Clinic to develop a cutting-edge digital confocal laser endomicroscopic imaging system specifically designed for use in robotic surgeries. The collaboration brings together Optiscan...

Optiscan signs deal with world-renowned Mayo Clinic AdAlta designates Cell Therapies as its manufacturing partner Ecofibre jumps after entering sell and leaseback agreement in US   Optiscan signs deal with Mayo Clinic Optiscan Imaging (AS...

ASX closed higher on Friday as energy stocks lifted Oil prices up as Middle East conflict intensifies US to impose new tariffs on China – covering electric vehicles, batteries, and solar cells    Aussie shares were on the up on Friday, c...

Optiscan Imaging says its latest financial results are just the tip of the iceberg, confident a stronger staff presence in the US health market will soon reap the rewards for its revolutionary medical devices.

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Several ASX medtech companies have upcoming catalysts in 2024 as they look to transform healthcare  Imricor preparing to treat its first ventricular tachycardia patient this quarter  Optiscan on schedule for launch of breast surgical devic...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. William J. O’Neil, the founder of Investor’s...

Medical device manufacturer Optiscan Imaging has expanded its U.S push, opening an office in the biotech hub of Minnesota with two well-credentialed hires.

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Special Report: Optiscan is beefing up its presence in the US as it works toward securing US regulatory approvals for its confocal endomicroscopic imaging technologies.  Optiscan (ASX:OIL) has started to ramp up its presence in the US after...

Optiscan Imaging (ASX:OIL) has announced the establishment of its US Regional Office in Rochester, Minnesota, and the appointment of two US-based heads of clinical and regulatory affairs.

Optiscan Imaging’s ongoing studies aimed at producing revolutionary medical imaging devices have received a timely financial boost through a $672,320 research and development tax rebate from the ATO.

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Early detection and effective treatment can lead to remission or cure for many cancers Optiscan’s tech brings surgeons and pathologists together to better diagnose, treat and monitor cancer Race Oncology’s working to minimise cardiovascula...

Stockhead’s Ashtyn Hiron sits down with Optiscan (ASX:OIL) CEO And Managing Director Dr. Camile Farah to get the short end of the long story on the company’s latest news. Optiscan received a $3 million dollar grant to work on its second-gen...

US inflation data came in higher than tipped, rattling the markets over there, with the ripple effect expected to reach the ASX200 today. Futures predict the local share market will shed 1.5 per cent for Valentine’s Day. The Nasdaq tu...

Optiscan Imaging is investigating how it can use AI in the cancer-fighting technology it believes could help create a multi-billion-dollar revenue stream in the United States, after receiving a $3m grant.

A money trail is forming behind Optiscan Imaging’s technology-based mission to tackle the scourge of cancer, with revenue starting to stream into the company’s coffers from the lucrative Chinese health sector.

Optiscan’s platform could help with shortage of pathologists in Australia and globally Platform particularly useful in diagnosing malignant tumours and pre-cancerous lesions in surgery Optiscan seeking US FDA De Novo clearance for its InV...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, which made announcements today.   ICYMI Lead...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Optiscan Imaging has strengthened its mission aimed at breaking into the US health market or with its “ViewnVivo” technology by putting key personnel on the ground on that country’s east and west coasts.

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Optiscan Imaging is on a mission to prove its technology can provide surgeons with the exact extent of breast cancer margins at the time of operating through the real-time diagnosis of affected tissues.

Optiscan Imaging (ASX:OIL) has provided an interim readout on its Breast Cancer Intraoperative Assessment Study.

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Optiscan Imaging has ticked off a major milestone in developing its telepathology platform, with the project passing its proof-of-concept stage amid plans for the software to completed by the end of next year.

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Optiscan Imaging says it has successfully raised $16.7 million from a recent entitlement issue as the company looks to pursue research and development projects, in addition to developing new clinical devices.

Optiscan Imaging has been invited to present its remarkable confocal endomicroscopic medical imaging technology at two key international conferences in North and South America.